Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy
- Author(s)
- Thompson, JR; Lai-Kwon, J; Morton, RL; Guminski, AD; Gonzalez, M; Atkinson, V; Sandhu, S; Brown, MP; Menzies, AM; McArthur, GA; Lo, SN; Long, GV; Bartula, I;
- Details
- Publication Year 2023-06,Volume 15,Issue #8,Page 593-610
- Journal Title
- Immunotherapy
- Publication Type
- Research article
- Abstract
- Aims: To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab-nivolumab or nivolumab treatment. Materials & methods: HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan-Meier method was used to determine median time to first deterioration. Results: Asymptomatic MBM patients treated with ipilimumab-nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement. Conclusion: MBM patients treated with either ipilimumab-nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation. Clinical trial registration: NCT02374242 (ClinicalTrials.gov).; Historically, people whose melanoma had spread to the brain (known as brain metastases) lived only 4-6 months after diagnosis, with less than 15% alive at 12 months. However, the development of immunotherapies such as nivolumab and ipilimumab to treat advanced melanoma has resulted in more than 50% of patients being alive 5 years after diagnosis. With the effectiveness of these immunotherapies demonstrated in clinical trials, we wanted to examine the impact of these treatments on the health-related quality of life of people with melanoma brain metastases. Using data from a clinical trial evaluating the effectiveness of immunotherapies in people diagnosed with melanoma brain metastases, this study investigated the impact of nivolumab and nivolumab combined with ipilimumab on quality of life. We found that neither nivolumab alone nor nivolumab combined with ipilimumab had a negative effect on quality of life. In summary, this study provides further support for the use of these immunotherapies as first-line treatment for melanoma brain metastases.; eng
- Publisher
- Future Medicine
- Keywords
- Humans; Nivolumab/adverse effects; Ipilimumab/adverse effects; Quality of Life; *Melanoma/drug therapy/pathology; *Brain Neoplasms/drug therapy/etiology; Immunotherapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; HRQoL; brain metastases; ipilimumab; melanoma; nivolumab
- Department(s)
- Medical Oncology
- PubMed ID
- 37132182
- Publisher's Version
- https://doi.org/10.2217/imt-2022-0262
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-09-05 06:33:32
Last Modified: 2023-09-05 06:34:32